Loading
NeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices. Its primary offering is IB-Stim, a percutaneous electrical nerve field stimulation system engineered to alleviate functional abdominal pain associated with irritable bowel syndrome in patients aged 11 to 18. NeurAxis markets its solutions to healthcare providers, predominantly hospitals and clinics. The firm, headquartered in Carmel, Indiana, was established in 2011 and operated as Innovative Health Solutions, Inc. until its rebranding to NeurAxis, Inc. in March 2022.
Latest quote
$6.93
+$0.16 · +2.36%
Regular session · ET · Market data may be delayed.
NeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices. Its primary offering is IB-Stim, a percutaneous electrical nerve field stimulation system engineered to alleviate functional abdominal pain associated with irritable bowel syndrome in patients aged 11 to 18. NeurAxis markets its solutions to healthcare providers, predominantly hospitals and clinics. The firm, headquartered in Carmel, Indiana, was established in 2011 and operated as Innovative Health Solutions, Inc. until its rebranding to NeurAxis, Inc. in March 2022.
Day range
Current $6.93
52-week range
Current $6.93
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
61
Undervalued
Sentiment
41
Mixed
Risk
53
Elevated Risk
Momentum
52
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
NeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices. Its primary offering is IB-Stim, a percutaneous electrical nerve field stimulation system engineered to alleviate functional abdominal pain associated with irritable bowel syndrome in patients aged 11 to 18. NeurAxis markets its solutions to healthcare providers, predominantly hospitals and clinics. The firm, headquartered in Carmel, Indiana, was established in 2011 and operated as Innovative Health Solutions, Inc. until its rebranding to NeurAxis, Inc. in March 2022.
Day range
Current $6.93
52-week range
Current $6.93
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 3.57M USD | 2.69M USD | 2.46M USD | 2.68M USD | 2.72M USD |
| Cost of goods sold | 562.92K USD | 362K USD | 303.35K USD | 297.06K USD | 467.66K USD |
| Gross profit | 3.01M USD | 2.32M USD | 2.16M USD | 2.39M USD | 2.25M USD |
| Research and development | 493.61K USD | 206.11K USD | 169.32K USD | 225.61K USD | 203.41K USD |
| Selling, general, and administrative | 10.34M USD | 9.27M USD | 8.65M USD | 5.53M USD | 5.02M USD |
| Operating expenses | 10.84M USD | 9.48M USD | 8.82M USD | 5.76M USD | 5.22M USD |
| Interest income | — | — | −2.77K USD | −2.32M USD | — |
| Interest expense | 73.97K USD | 300.72K USD | 5.36M USD | 417.6K USD | 36.93K USD |
| Depreciation and amortization | 59.5K USD | 37.83K USD | 40.73K USD | 37.13K USD | 36.71K USD |
| Operating income | −7.83M USD | −7.16M USD | −6.66M USD | −3.37M USD | −2.97M USD |
| Net income | −7.8M USD | −8.24M USD | −14.63M USD | −4.78M USD | −3.03M USD |
Company facts updated Oct 10, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$8.00
15.44% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI1.34M0.00%2.3T USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF658.44K0.00%95.4B USD0.05%$235+0.80%
iShares Micro-Cap ETFIWC207.24K0.02%1.32B USD0.60%$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM110K0.10%116.54M USD0.73%$15.9402+0.25%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
